Kyverna plans to submit mivocabtagene autoleucel to the FDA for approval in the first half of 2026. If approved, it would be ...
The CAR T-cell therapy market offers significant growth opportunities driven by technological advancements, personalized ...
The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...
MedPage Today on MSN
Gene Therapy-Induced CAR T Cells for Myeloma Could Alter Treatment Landscape
ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...
An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...
Lisocabtagene maraleucel (liso-cel) is now the only CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for MZL. The approval marks liso-cel’s fifth indication, the most of any ...
Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.
The advent of chimeric antigen receptor (CAR)-T cell therapy has marked the onset of a very promising option to treat solid tumors after its remarkable ...
Engineered immune cells are being used to successfully treat people with a range of debilitating autoimmune conditions, such as ulcerative colitis, rheumatoid arthritis and lupus. Researchers say ...
Potent CAR-T expansion from a single, off-the-shelf infusion without chemotherapy ...
A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback